NAUT · 10-Q · 2026Q1 · Full report

Research and Development Expense

Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 48 · Surprise 40

Research and development expenses were $9.7 million for the three months ended March 31, 2026, down from $11.5 million in the three months ended March 31, 2025, a decrease of $1.8 million, or 16%. The decrease included a $1.0 million reduction in salaries and related benefits tied to the reduction in force implemented in Q1 2025. Other contributors to the decline were $0.2 million lower facilities expense and $0.2 million lower stock-based compensation expense. Laboratory and professional services expense also decreased by $0.2 million year over year.

Key facts

• Research and development expenses were $9,707,000 for the three months ended March 31, 2026, compared to $11,536,000 for the three months ended March 31, 2025, a decrease of $1,829,000 or 16%.
• The decrease in research and development expense for the three months ended March 31, 2026 was due to a $1.0 million decrease in salaries and related benefits, a $0.2 million decrease in facilities expense, a $0.2 million decrease in stock-based compensation, and a $0.2 million decrease in laboratory and professional services.

Impact estimates